Crinetics Pharmaceuticals, Inc. filings document a commercial-stage pharmaceutical company focused on endocrine diseases and endocrine-related tumors. Its 8-K reports include financial results and business updates tied to PALSONIFY product revenue, clinical development activity, regulatory matters, and corporate presentations. The filings also identify the company’s common stock, traded under CRNX on the Nasdaq Global Select Market.
Crinetics’ regulatory record also includes proxy materials covering governance and executive compensation, as well as current reports on officer responsibilities, executive departures, consulting arrangements, and changes in the company’s independent registered public accounting firm. These disclosures place PALSONIFY commercialization and endocrine pipeline development within formal reporting categories for operations, governance, controls, and capital-market status.
Crinetics Pharmaceuticals, Inc. (CRNX) reported that Chief Financial & Infra. Officer Tobin Schilke’s equity awards were cashed out in connection with the merger under which Crinetics became a wholly owned subsidiary of Vertex Pharmaceuticals, effective September 1, 2026. Each Crinetics common share was canceled and converted into the right to receive $85.00 per share in cash.
The filing shows disposition to the issuer of 7,956 common shares at $85.00 per share and the cancellation of 71,471 restricted stock units, each converted into cash equal to the $85.00 merger price, less tax withholding. It also reports the cancellation of 80,000 and 50,000 stock options, each converted into cash equal to the $85.00 merger price minus the respective exercise prices, with unvested options and RSUs vesting immediately before the merger.
Crinetics Pharmaceuticals, Inc. (CRNX) reports that, effective September 1, 2026, it became a wholly owned subsidiary of Vertex Pharmaceuticals under an Agreement and Plan of Merger. At the effective time, each outstanding share of Crinetics common stock was canceled and converted into the right to receive $85.00 in cash per share, subject to tax withholding. The filing shows cancellation of both directly and indirectly held common shares (including spouse, family trusts, and a charitable trust) and cancellation of various employee stock options and restricted stock units, which were converted into cash equal to the merger consideration (or, for options, the cash difference between the $85.00 merger price and the option exercise price).
Crinetics Pharmaceuticals, Inc. (CRNX) has had its common stock the subject of a Form 25 filing by Nasdaq Stock Market LLC to remove the class of securities from listing and/or registration under Section 12(b) of the Securities Exchange Act of 1934. The notification states that the exchange has complied with its rules and with 17 CFR 240.12d2-2(b), and that the issuer has complied with the exchange’s rules and the requirements of 17 CFR 240.12d2-2(c) governing withdrawal of the class from listing and registration. The filing is signed on behalf of Nasdaq by an authorized officer.
Crinetics Pharmaceuticals, Inc. (CRNX) completed its merger with Vertex Pharmaceuticals Incorporated on September 1, 2026. Clark Merger Sub, Inc. merged with and into Crinetics, which now continues as the surviving corporation and a wholly owned subsidiary of Vertex.
At the Effective Time, each issued and outstanding share of Crinetics common stock (with customary exceptions) was canceled and converted into the right to receive $85.00 in cash per share, subject to withholding taxes. Unvested stock options and restricted stock units fully vested; in-the-money options and RSUs were cashed out based on the $85.00 price, while out-of-the-money options were canceled for no consideration. Crinetics’ equity and employee stock plans and its at-the-market Sales Agreement with SVB Leerink LLC and Cantor Fitzgerald & Co. were terminated. Trading in CRNX on Nasdaq was suspended, and Crinetics requested delisting via Form 25, to be followed by Form 15 to terminate registration and suspend reporting obligations. An aggregate of approximately $10.0 billion was paid by Vertex using cash on hand and term loan borrowings. All Crinetics directors and officers resigned at closing and were replaced by Vertex designees, and Crinetics’ certificate of incorporation and bylaws were amended and restated in accordance with the Merger Agreement.
Crinetics Pharmaceuticals, Inc. (CRNX) reported results of its August 28, 2026 special shareholders meeting to vote on its proposed acquisition by Vertex Pharmaceuticals. Of 106,095,205 common shares outstanding and entitled to vote as of July 27, 2026, 79,264,631 shares were represented in person or by proxy, a 74.71% quorum.
Shareholders approved the Merger Proposal to adopt the July 6, 2026 Merger Agreement among Crinetics, Vertex and Clark Merger Sub, Inc., under which Merger Sub will merge with and into Crinetics and Crinetics will become a wholly owned subsidiary of Vertex. Proposal 1 received 79,240,098 votes for, 13,618 against and 10,915 abstentions. An advisory proposal on merger-related executive compensation (Proposal 2) did not receive the requisite support, but is non-binding and not a condition to closing. Proposal 3, an adjournment proposal, was not presented because sufficient votes were obtained for the Merger Proposal. With shareholder approval, the final outstanding condition to closing the Merger is satisfied, and Crinetics anticipates closing on or about September 1, 2026.
Crinetics Pharmaceuticals, Inc. (CRNX) reported that Chief Financial & Infra. Ofcr. Tobin Schilke received a grant of 471 restricted stock units (RSUs) of common stock. These RSUs vest 25% annually beginning on September 1, 2027. Following this award, Schilke directly holds 79,427 shares of common stock, including 835 shares acquired through the company’s Employee Stock Purchase Plan.
Crinetics Pharmaceuticals, Inc. (CRNX) filed an update related to its pending all-cash merger with Vertex Pharmaceuticals, under which Vertex will acquire Crinetics for $85.00 per share, implying an equity value of approximately $10 billion. A special shareholder meeting to vote on the merger is scheduled for August 28, 2026, and the board continues to unanimously recommend voting in favor of the merger and related proposals.
Crinetics disclosed shareholder lawsuits and demand letters alleging deficiencies in the proxy disclosures and stated that it believes these claims are without merit, but is voluntarily providing supplemental disclosures. These include more detail on the board’s process, a pending derivative action over director compensation, and expanded summaries of valuation work by J.P. Morgan and Leerink Partners, such as revenue-based trading multiples, discounted cash flow assumptions, management forecasts through 2045, and advisory fee arrangements. The projections include risk‑adjusted total revenue of $1,057 million in 2030, significant net operating loss carryforwards and net cash, which both advisors used in their fairness analyses when comparing to the $85.00 merger consideration.
Crinetics Pharmaceuticals, Inc. reports further progress toward its planned acquisition by Vertex Pharmaceuticals. The Hart-Scott-Rodino waiting period for the merger expired at 12:45 p.m. Eastern Time on August 12, 2026, and required antitrust approvals in Austria, Germany and Australia have been received, with an Australian waiting period scheduled to expire on August 27, 2026 at 9:59 a.m. Eastern Time.
The merger still depends on remaining closing conditions, including adoption of the merger by Crinetics’ shareholders at a special meeting on August 28, 2026. Assuming shareholder approval, the companies expect the merger and related transactions to close in early September 2026. Crinetics highlights extensive forward‑looking risks and directs shareholders to its definitive proxy statement filed July 31, 2026 for detailed information.